Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

IONS

Ionis Pharmaceuticals Inc

Sep 20 • 04:00PM ET

42.76

Dollar change +0.02
Percentage change 0.05	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI VB VXF VBK XBI ARKG IBB IWP SCHA IWF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.53	Insider Own	8.31%	Shs Outstand	157.71M	Perf Week	1.35%
Market Cap	6.74B	Forward P/E	-	EPS next Y	-3.39	Insider Trans	-0.33%	Shs Float	144.60M	Perf Month	-11.25%
Income	-365.48M	PEG	-	EPS next Q	-1.11	Inst Own	90.03%	Short Float	7.03%	Perf Quarter	2.22%
Sales	813.95M	P/S	8.29	EPS this Y	-38.56%	Inst Trans	-4.20%	Short Ratio	6.29	Perf Half Y	0.02%
Book/sh	1.81	P/B	23.68	EPS next Y	4.33%	ROA	-12.91%	Short Interest	10.16M	Perf Year	0.52%
Cash/sh	13.18	P/C	3.24	EPS next 5Y	35.30%	ROE	-105.63%	52W Range	35.95 - 54.44	Perf YTD	-15.48%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-16.64%	52W High	-21.46%	Beta	0.39
Dividend TTM	-	Quick Ratio	7.51	Sales past 5Y	13.97%	Gross Margin	95.83%	52W Low	18.94%	ATR (14)	1.70
Dividend Ex-Date	-	Current Ratio	7.61	EPS Y/Y TTM	-16.73%	Oper. Margin	-44.83%	RSI (14)	41.48	Volatility	3.28% 3.61%
Employees	927	Debt/Eq	7.50	Sales Y/Y TTM	29.06%	Profit Margin	-44.90%	Recom	1.74	Target Price	61.73
Option/Short	Yes / Yes	LT Debt/Eq	7.33	EPS Q/Q	23.83%	Payout	-	Rel Volume	1.59	Prev Close	42.74
Sales Surprise	44.15%	EPS Surprise	51.36%	Sales Q/Q	19.55%	Earnings	Aug 01 BMO	Avg Volume	1.62M	Price	42.76
SMA20	-6.04%	SMA50	-9.52%	SMA200	-6.33%	Trades		Volume	2,566,873	Change	0.05%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-02-24	Downgrade	BMO Capital Markets	Outperform → Market Perform	$67 → $60
Jul-24-24	Upgrade	Leerink Partners	Market Perform → Outperform	$53 → $62
Jul-16-24	Resumed	Jefferies	Buy	$29 → $75
Jun-14-24	Upgrade	Bernstein	Underperform → Mkt Perform	$44
Apr-10-24	Upgrade	Wolfe Research	Peer Perform → Outperform	$58
Jan-02-24	Upgrade	BofA Securities	Neutral → Buy	$52 → $62
Oct-23-23	Upgrade	BofA Securities	Underperform → Neutral	$33 → $52
Sep-29-23	Initiated	Raymond James	Strong Buy	$63
Jul-31-23	Upgrade	Citigroup	Neutral → Buy	$36 → $60
Jun-07-23	Resumed	Piper Sandler	Overweight	$58
May-04-23	Upgrade	Citigroup	Sell → Neutral	$30 → $36
Mar-21-23	Initiated	Bernstein	Underperform	$31
Dec-21-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$56 → $40
Sep-09-22	Resumed	Morgan Stanley	Overweight	$57
Jul-18-22	Resumed	Oppenheimer	Outperform	$59
Mar-31-22	Resumed	Piper Sandler	Overweight	$54
Mar-01-22	Initiated	Guggenheim	Buy	$64
Mar-01-22	Initiated	Citigroup	Sell	$26
Feb-01-22	Downgrade	BofA Securities	Buy → Underperform	$40 → $30
Dec-14-21	Upgrade	William Blair	Mkt Perform → Outperform

Show Previous Ratings

Sep-12-24 01:01PM	The Brawl Taking Shape Over Pfizers Multibillion-Dollar Heart Monopoly (The Wall Street Journal)
Sep-09-24 09:10PM	Ionis announces pricing of $500.3 million public offering (PR Newswire) -12.29%
04:20PM	Ionis announces proposed public offering of common stock (PR Newswire)
Sep-04-24 08:00AM	Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations (GlobeNewswire)
07:30AM	Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA (GlobeNewswire)
07:05AM	Loading…
Aug-28-24 07:05AM	Ionis to present at upcoming investor conferences (PR Newswire)
Aug-15-24 09:15AM	Will Ionis' (IONS) Wholly-Owned Drugs Drive Future Growth? (Zacks)
Aug-13-24 07:00AM	Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-06-24 11:34PM	Insider Sale at Ionis Pharmaceuticals Inc (IONS) by EVP, Chief Development Officer Richard Geary (GuruFocus.com)
Aug-02-24 01:32PM	Analyst Report: Ionis Pharmaceuticals, Inc. (Morningstar Research)
09:54AM	Ionis (IONS) Q2 Earnings and Revenues Beat, Stock Rises (Zacks)
04:34AM	Q2 2024 Ionis Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-01-24 10:00AM	Ionis Pharmaceuticals (IONS) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
08:20AM	Ionis Pharmaceuticals (IONS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:32AM	Ionis Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Loading…
07:00AM	Ionis reports second quarter 2024 financial results (PR Newswire)
Jul-31-24 09:00AM	Alcyone Therapeutics Announces Continued Enrollment Approval from FDA of the PIERRE Pivotal IDE Clinical Study of the ThecaFlex DRx System for Administration of nusinersen (PR Newswire)
Jul-25-24 10:02AM	Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Jul-23-24 09:53AM	Ionis (IONS) Up 6% on Detailed Data From Angelman Drug Study (Zacks)
07:03AM	Ionis Pharmaceuticals reports data from Phase I/II trial of Angelman syndrome drug (Clinical Trials Arena)
Jul-22-24 04:27PM	Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong (Investor's Business Daily) +5.83%
08:14AM	Ionis plots next steps for Angelman drug Biogen passed on (BioPharma Dive)
07:00AM	Ionis announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndrome (PR Newswire)
Jul-19-24 09:56AM	Ionis (IONS) Completes Enrolment for Rare Disease Drug Study (Zacks)
08:24AM	Ionis to hold second quarter 2024 financial results webcast (PR Newswire)
06:32AM	Ionis completes subject enrolment in Alexander disease treatment trial (Clinical Trials Arena)
Jul-18-24 07:00AM	Ionis completes enrollment in pivotal trial evaluating zilganersen in people living with Alexander disease (PR Newswire)
Jul-17-24 08:00AM	Alltrna Announces Updates to Its Board of Directors (PR Newswire)
Jul-08-24 07:05AM	Ionis announces webcast to report HALOS study results for ION582 in Angelman syndrome (PR Newswire)
Jun-26-24 12:56PM	FDA Accepts Ionis' (IONS) NDA for Rare Disease Drug Olezarsen (Zacks)
06:55AM	Loading…
Jun-25-24 06:55AM	Ionis announces olezarsen FCS New Drug Application accepted for Priority Review and enrollment in Phase 3 sHTG program completed (PR Newswire) +5.19%
06:30AM	Ionis Pharmaceuticals (IONS) Soars 6.8%: Is Further Upside Left in the Stock? (Zacks)
Jun-19-24 12:11PM	Ionis (IONS) Expands Licensing Deal With Otsuka for HAE Drug (Zacks)
Jun-18-24 07:00AM	Ionis announces expanded licensing agreement with Otsuka in Asia Pacific for investigational medicine donidalorsen in hereditary angioedema (PR Newswire)
Jun-17-24 04:09PM	Ionis to present at TD Cowen Genetic Medicines & RNA Summit (PR Newswire)
Jun-06-24 11:31AM	Ionis Pharmaceuticals (IONS) Down 0.7% Since Last Earnings Report: Can It Rebound? (Zacks)
May-31-24 12:25PM	Europe Approves Biogen's Tofersen For Adult Patients With Rare Type Of Neurodegenerative Disorder (Benzinga)
07:00AM	Ionis presents positive results from OASIS-HAE and OASISplus studies of investigational medicine donidalorsen in patients with hereditary angioedema (PR Newswire)
May-28-24 07:00AM	Ionis to hold donidalorsen Phase 3 data webcast (PR Newswire)
May-23-24 07:00AM	New data from the Phase 3 NEURO-TTRansform study evaluating WAINUA (eplontersen) to be presented at the 2024 International Symposium on Amyloidosis (ISA) (PR Newswire)
May-17-24 10:10AM	Ionis (IONS), Biogen Down on Ending Development of ALS Drug (Zacks)
May-16-24 12:46PM	Top Stock Movers Now: Walmart, Canada Goose, Deere, and More (Investopedia)
10:54AM	Ionis Pharmaceuticals Says Potential Angelman Syndrome Therapy Improves Symptoms in Phase 1/2a Study (MT Newswires)
08:50AM	Biogen, Ionis to Cease BIIB105 ALS Investigational Drug Development Following Phase 1/2 Trial Results (MT Newswires)
08:05AM	Biogen, Ionis shelve ALS drug following study failure (BioPharma Dive)
07:51AM	REFILE-UPDATE 2-Biogen, Ionis to discontinue development of experimental ALS drug (Reuters)
07:37AM	Biogen, Ionis will discontinue development of their ALS drug (Reuters)
07:30AM	Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis (PR Newswire)
07:30AM	Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis (GlobeNewswire)
07:00AM	Ionis announces positive topline results from Phase 1/2a trial of ION582 for Angelman syndrome (PR Newswire)
May-15-24 07:05AM	Ionis to host 2024 virtual Annual Meeting of Stockholders (PR Newswire)
May-13-24 07:00AM	Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-09-24 06:30AM	The 3 Most Undervalued Pharma Stocks to Buy in May 2024 (InvestorPlace)
May-08-24 03:15PM	Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q1 2024 Earnings Call Transcript (Insider Monkey)
10:59AM	Wells Fargo Adjusts Ionis Pharmaceuticals Price Target to $82 From $85, Maintains Overweight Rating (MT Newswires)
10:39AM	Ionis (IONS) Q1 Loss Narrower Than Expected, Sales Miss (Zacks)
05:20AM	Q1 2024 Ionis Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
03:40AM	Ionis Pharmaceuticals Inc (IONS) Q1 2024 Earnings Call Transcript Highlights: Key Developments ... (GuruFocus.com)
May-07-24 05:02PM	Ionis Pharmaceuticals Insider Sold Shares Worth $256,277, According to a Recent SEC Filing (MT Newswires)
04:43PM	Analyst Report: Ionis Pharmaceuticals, Inc. (Morningstar Research)
09:30AM	Ionis Pharmaceuticals (IONS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
08:10AM	Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
08:07AM	Ionis Pharmaceuticals Q1 Net Loss Widens as Revenue Falls (MT Newswires)
07:07AM	Ionis Pharmaceuticals: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Ionis reports first quarter 2024 financial results (PR Newswire)
May-06-24 09:15AM	Wall Street's Insights Into Key Metrics Ahead of Ionis Pharmaceuticals (IONS) Q1 Earnings (Zacks)
Apr-30-24 10:00AM	Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks)
Apr-25-24 07:00AM	Ionis Publishes 2023 Corporate Responsibility Report (PR Newswire)
Apr-23-24 07:05AM	Ionis to hold first quarter 2024 financial results webcast (PR Newswire)
Apr-07-24 09:48AM	Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome (PR Newswire)
Apr-01-24 07:05AM	Ionis to present at upcoming investor conferences (PR Newswire)
Mar-28-24 07:05AM	Ionis to hold olezarsen Phase 3 data webcast (PR Newswire)
Mar-25-24 09:09AM	Can Ionis' (IONS) Wholly-Owned Drugs Cut Dependency on Collabs? (Zacks)
08:18AM	Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meeting (PR Newswire)
Mar-22-24 11:30AM	Ionis Pharmaceuticals (IONS) Down 2.8% Since Last Earnings Report: Can It Rebound? (Zacks)
Mar-21-24 03:00PM	New Blood Thinners Will Prevent Blood Clots Without Causing Bleeding (The Wall Street Journal)
Mar-17-24 08:50AM	30 Biggest Biotechnology Companies in the World (Insider Monkey)
Mar-14-24 10:40AM	Ionis (IONS) Drug Meets Mid-Stage MASH Study Goals (Zacks)
Mar-13-24 07:17AM	UPDATE 1-Ionis Pharma's fatty liver disease drug succeeds in mid-stage trial (Reuters)
07:07AM	Ionis Pharma's fatty liver disease drug succeeds in mid-stage trial (Reuters)
07:00AM	Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASH (PR Newswire)
Mar-06-24 07:30AM	New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy (GlobeNewswire)
Feb-29-24 09:05AM	Ionis announces new chief global product strategy officer to lead next phase of commercial growth (PR Newswire)
Feb-28-24 07:05AM	Ionis to present at upcoming investor conferences (PR Newswire)
Feb-22-24 12:12PM	Analyst Report: Ionis Pharmaceuticals, Inc. (Morningstar Research)
10:59AM	Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q4 2023 Earnings Call Transcript (Insider Monkey)
10:29AM	Ionis (IONS) Q4 Loss Narrower Than Expected, Sales Surge Y/Y (Zacks)
02:20AM	Q4 2023 Ionis Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-21-24 11:31AM	Ionis Pharmaceuticals Inc (IONS) Surpasses Revenue Guidance for 2023, Sets Sights on 2024 Growth (GuruFocus.com)
09:30AM	Ionis Pharmaceuticals (IONS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
08:05AM	Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:06AM	Ionis Pharmaceuticals: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Ionis reports fourth quarter and full year 2023 financial results (PR Newswire)
Feb-15-24 09:15AM	Ionis Pharmaceuticals (IONS) Q4 Earnings Preview: What You Should Know Beyond the Headline Estimates (Zacks) -7.72%
07:00AM	Olezarsen receives Orphan Drug designation from U.S. FDA for familial chylomicronemia syndrome (PR Newswire)
Feb-14-24 10:00AM	Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks)
Feb-09-24 10:44AM	Ionis' (IONS) Eplontersen Gets Fast Track Tag for New Indication (Zacks)
Feb-08-24 07:00AM	Eplontersen granted U.S. FDA Fast Track designation for patients with transthyretin-mediated amyloid cardiomyopathy (PR Newswire)
Feb-07-24 07:05AM	Ionis to hold fourth quarter and full year 2023 financial results webcast (PR Newswire)
Jan-23-24 01:23PM	Ionis' (IONS) Donidalorsen Meets Late-Stage HAE Study Goal (Zacks)

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core segment. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia on January 10, 1989 and is headquartered in Carlsbad, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Geary Richard S	EVP, Chief Development Officer	Aug 29 '24	Sale	49.63	331	16,428	84,823	Sep 03 07:18 PM
Geary Richard S	EVP, Chief Development Officer	Aug 28 '24	Sale	49.16	320	15,731	85,154	Sep 03 07:18 PM
Geary Richard S	EVP, Chief Development Officer	Aug 05 '24	Sale	48.00	2,430	116,640	85,508	Aug 06 05:27 PM
Geary Richard S	Executive Vice President, Chie	Aug 05 '24	Proposed Sale	49.13	3,128	153,678		Aug 05 04:11 PM
WENDER JOSEPH H	Director	Jul 15 '24	Option Exercise	0.00	4,677	0	132,756	Jul 17 05:03 PM
PARSHALL B LYNNE	Director	Jul 15 '24	Option Exercise	0.00	4,677	0	87,265	Jul 17 05:03 PM
LOSCALZO JOSEPH	Director	Jul 15 '24	Option Exercise	0.00	4,677	0	45,759	Jul 17 05:03 PM
KLEIN JOSEPH III	Director	Jul 16 '24	Option Exercise	24.42	12,000	293,040	12,000	Jul 17 05:02 PM
KLEIN JOSEPH III	Director	Jul 16 '24	Sale	50.00	12,000	600,000	0	Jul 17 05:02 PM
HERMAN JOAN E	Director	Jul 15 '24	Option Exercise	0.00	4,677	0	42,007	Jul 17 05:02 PM
Diaz Allene M.	Director	Jul 15 '24	Option Exercise	0.00	4,677	0	17,353	Jul 17 05:02 PM
Diaz Allene M.	Director	Jul 16 '24	Sale	49.49	1,637	81,019	15,716	Jul 17 05:02 PM
BERTHELSEN SPENCER R	Director	Jul 15 '24	Option Exercise	0.00	4,677	0	151,934	Jul 17 05:02 PM
BERTHELSEN SPENCER R	Director	Jun 17 '24	Option Exercise	35.53	16,000	568,480	163,257	Jun 20 05:52 PM
BERTHELSEN SPENCER R	Director	Jun 17 '24	Sale	40.29	16,000	644,640	147,257	Jun 20 05:52 PM
WENDER JOSEPH H	Director	May 09 '24	Option Exercise	35.53	16,000	568,480	128,079	May 13 05:25 PM
KLEIN JOSEPH III	Director	May 03 '24	Sale	42.71	6,000	256,277	0	May 07 04:55 PM
Baroldi Joseph	EVP, Chief Business Officer	Apr 15 '24	Option Exercise	0.00	10,838	0	23,637	Apr 17 05:19 PM
Baroldi Joseph	EVP, Chief Business Officer	Apr 16 '24	Sale	41.60	4,006	166,641	19,631	Apr 17 05:19 PM
Birchler Brian	EVP, Corp and Development Ops	Apr 15 '24	Option Exercise	0.00	1,875	0	47,061	Apr 17 05:16 PM
Birchler Brian	EVP, Corp and Development Ops	Apr 16 '24	Sale	41.66	905	37,698	46,156	Apr 17 05:16 PM
Monia Brett P	Chief Executive Officer	Feb 16 '24	Sale	44.49	387	17,219	173,751	Feb 16 07:47 PM
Swayze Eric	EVP Research	Jan 31 '24	Sale	52.00	10,773	560,196	32,516	Feb 02 07:55 PM
Swayze Eric	EVP Research	Feb 02 '24	Sale	49.56	1,907	94,513	34,324	Feb 02 07:55 PM
Schneider Eugene	EVP, Chf Clinical Develop Ofcr	Feb 02 '24	Sale	49.59	2,071	102,701	49,812	Feb 02 07:55 PM
O'NEIL PATRICK R.	EVP CLO & General Counsel	Feb 02 '24	Sale	49.67	1,961	97,410	48,661	Feb 02 07:55 PM
Monia Brett P	Chief Executive Officer	Feb 02 '24	Sale	49.37	23,501	1,160,303	174,138	Feb 02 07:55 PM
HOUGEN ELIZABETH L	EVP, Finance & CFO	Feb 02 '24	Sale	49.54	2,125	105,272	92,905	Feb 02 07:55 PM
Geary Richard S	EVP, Chief Development Officer	Feb 02 '24	Sale	50.04	1,961	98,135	87,334	Feb 02 07:54 PM
Cadoret-Manier Onaiza	EVP, Chf GL Pdt Str & Oper Ofc	Feb 02 '24	Sale	49.60	2,125	105,404	35,825	Feb 02 07:54 PM
BENNETT C FRANK	EVP, Chief Scientific Officer	Feb 02 '24	Sale	49.52	1,853	91,752	79,079	Feb 02 07:54 PM
Monia Brett P	Chief Executive Officer	Jan 25 '24	Sale	51.75	2,285	118,249	151,851	Jan 29 05:34 PM
O'NEIL PATRICK R.	EVP CLO & General Counsel	Jan 25 '24	Sale	51.75	6,450	333,788	46,802	Jan 29 05:34 PM
Cadoret-Manier Onaiza	EVP, Chf GL Pdt Str & Oper Ofc	Jan 16 '24	Option Exercise	0.00	15,062	0	39,374	Jan 18 06:07 PM
Cadoret-Manier Onaiza	EVP, Chf GL Pdt Str & Oper Ofc	Jan 17 '24	Sale	50.42	5,564	280,520	33,810	Jan 18 06:07 PM
O'NEIL PATRICK R.	EVP CLO & General Counsel	Jan 16 '24	Option Exercise	0.00	20,641	0	60,996	Jan 18 05:59 PM
O'NEIL PATRICK R.	EVP CLO & General Counsel	Jan 17 '24	Sale	50.42	7,744	390,429	53,252	Jan 18 05:59 PM
Birchler Brian	EVP, Corp and Development Ops	Jan 16 '24	Option Exercise	0.00	12,080	0	49,079	Jan 18 05:55 PM
Birchler Brian	EVP, Corp and Development Ops	Jan 17 '24	Sale	50.42	4,497	226,725	44,582	Jan 18 05:55 PM
Swayze Eric	EVP Research	Jan 16 '24	Option Exercise	0.00	21	0	94	Jan 18 05:49 PM
Swayze Eric	EVP Research	Jan 16 '24	Option Exercise	0.00	17,069	0	49,585	Jan 18 05:49 PM
Swayze Eric	EVP Research	Jan 17 '24	Sale	50.42	6,296	317,425	43,289	Jan 18 05:49 PM
Swayze Eric	EVP Research	Jan 17 '24	Sale	50.42	9	454	85	Jan 18 05:49 PM
Schneider Eugene	EVP, Chf Clinical Develop Ofcr	Jan 16 '24	Option Exercise	0.00	15,162	0	53,332	Jan 18 05:48 PM
Schneider Eugene	EVP, Chf Clinical Develop Ofcr	Jan 17 '24	Sale	50.42	5,482	276,386	47,850	Jan 18 05:48 PM
Monia Brett P	Chief Executive Officer	Jan 16 '24	Option Exercise	0.00	68,084	0	186,195	Jan 18 05:48 PM
Monia Brett P	Chief Executive Officer	Jan 17 '24	Sale	50.42	32,059	1,616,319	154,136	Jan 18 05:48 PM
HOUGEN ELIZABETH L	EVP, Finance & CFO	Jan 16 '24	Option Exercise	0.00	22,487	0	99,573	Jan 18 05:48 PM
HOUGEN ELIZABETH L	EVP, Finance & CFO	Jan 17 '24	Sale	50.42	8,683	437,771	90,890	Jan 18 05:48 PM
Geary Richard S	EVP, Chief Development Officer	Jan 16 '24	Option Exercise	0.00	19,852	0	92,813	Jan 18 05:47 PM
Geary Richard S	EVP, Chief Development Officer	Jan 17 '24	Sale	50.42	7,338	369,960	85,475	Jan 18 05:47 PM
BENNETT C FRANK	EVP, Chief Scientific Officer	Jan 16 '24	Option Exercise	0.00	18,314	0	84,068	Jan 18 05:44 PM
BENNETT C FRANK	EVP, Chief Scientific Officer	Jan 17 '24	Sale	50.42	6,745	340,063	77,323	Jan 18 05:44 PM
Baroldi Joseph	EVP, Chief Business Officer	Jan 16 '24	Option Exercise	0.00	1,353	0	2,204	Jan 18 05:44 PM
Baroldi Joseph	EVP, Chief Business Officer	Jan 16 '24	Option Exercise	0.00	3,688	0	14,259	Jan 18 05:44 PM
Baroldi Joseph	EVP, Chief Business Officer	Jan 17 '24	Sale	50.42	1,460	73,609	12,799	Jan 18 05:44 PM
Baroldi Joseph	EVP, Chief Business Officer	Jan 17 '24	Sale	50.42	564	28,435	1,640	Jan 18 05:44 PM
Schneider Eugene	EVP, Chf Clinical Develop Ofcr	Jan 12 '24	Option Exercise	32.60	8,000	260,800	46,170	Jan 17 08:51 PM
Schneider Eugene	EVP, Chf Clinical Develop Ofcr	Jan 12 '24	Sale	53.50	8,000	427,999	38,170	Jan 17 08:51 PM
Swayze Eric	EVP Research	Dec 28 '23	Option Exercise	47.34	27,100	1,282,914	59,616	Jan 02 05:54 PM
Swayze Eric	EVP Research	Dec 28 '23	Sale	50.19	27,100	1,360,081	32,516	Jan 02 05:54 PM
HOUGEN ELIZABETH L	EVP, Finance & CFO	Dec 28 '23	Option Exercise	47.34	45,225	2,140,952	120,884	Jan 02 05:54 PM
Birchler Brian	EVP, Corp and Development Ops	Dec 28 '23	Option Exercise	47.34	11,500	544,410	48,028	Jan 02 05:54 PM
O'NEIL PATRICK R.	EVP CLO & General Counsel	Dec 26 '23	Option Exercise	47.34	20,825	985,856	61,180	Dec 28 07:18 PM
O'NEIL PATRICK R.	EVP CLO & General Counsel	Dec 26 '23	Sale	51.46	20,825	1,071,717	40,355	Dec 28 07:18 PM
PARSHALL B LYNNE	Director	Dec 27 '23	Option Exercise	47.34	50,000	2,367,000	132,588	Dec 28 07:18 PM
PARSHALL B LYNNE	Director	Dec 28 '23	Option Exercise	47.34	42,525	2,013,134	125,113	Dec 28 07:18 PM
PARSHALL B LYNNE	Director	Dec 26 '23	Option Exercise	47.34	25,113	1,188,849	107,701	Dec 28 07:18 PM
PARSHALL B LYNNE	Director	Dec 27 '23	Sale	50.23	50,000	2,511,515	82,588	Dec 28 07:18 PM
PARSHALL B LYNNE	Director	Dec 28 '23	Sale	50.19	42,525	2,134,223	82,588	Dec 28 07:18 PM
PARSHALL B LYNNE	Director	Dec 26 '23	Sale	51.46	25,113	1,292,390	82,588	Dec 28 07:18 PM
Schneider Eugene	EVP, Chf Clinical Develop Ofcr	Dec 26 '23	Option Exercise	47.34	25,000	1,183,500	61,052	Dec 28 07:18 PM
Schneider Eugene	EVP, Chf Clinical Develop Ofcr	Dec 26 '23	Sale	51.46	25,000	1,286,575	36,052	Dec 28 07:18 PM
BENNETT C FRANK	EVP, Chief Scientific Officer	Dec 21 '23	Option Exercise	47.34	16,113	762,789	81,867	Dec 22 07:11 PM
BENNETT C FRANK	EVP, Chief Scientific Officer	Dec 20 '23	Option Exercise	47.34	6,500	307,710	72,254	Dec 22 07:11 PM
BENNETT C FRANK	EVP, Chief Scientific Officer	Dec 21 '23	Sale	49.29	16,113	794,211	65,754	Dec 22 07:11 PM
BENNETT C FRANK	EVP, Chief Scientific Officer	Dec 20 '23	Sale	49.64	6,500	322,643	65,754	Dec 22 07:11 PM
Geary Richard S	EVP, Chief Development Officer	Dec 20 '23	Option Exercise	47.34	6,500	307,710	79,461	Dec 22 07:11 PM
Geary Richard S	EVP, Chief Development Officer	Dec 21 '23	Option Exercise	47.34	4,112	194,662	77,073	Dec 22 07:11 PM
Geary Richard S	EVP, Chief Development Officer	Dec 20 '23	Sale	49.64	6,500	322,643	72,961	Dec 22 07:11 PM
Geary Richard S	EVP, Chief Development Officer	Dec 21 '23	Sale	49.29	4,112	202,681	72,961	Dec 22 07:11 PM
Monia Brett P	Chief Executive Officer	Dec 21 '23	Option Exercise	47.34	17,500	828,450	135,611	Dec 22 07:11 PM
Monia Brett P	Chief Executive Officer	Dec 20 '23	Option Exercise	47.34	6,500	307,710	124,611	Dec 22 07:11 PM
Monia Brett P	Chief Executive Officer	Dec 21 '23	Sale	49.29	17,500	862,577	118,111	Dec 22 07:11 PM
Monia Brett P	Chief Executive Officer	Dec 20 '23	Sale	49.64	6,500	322,643	118,111	Dec 22 07:11 PM
Monia Brett P	Chief Executive Officer	Dec 14 '23	Option Exercise	47.34	24,000	1,136,160	132,971	Dec 18 04:56 PM
Monia Brett P	Chief Executive Officer	Dec 14 '23	Sale	49.58	24,000	1,190,019	118,111	Dec 18 04:56 PM
Geary Richard S	EVP, Chief Development Officer	Dec 14 '23	Option Exercise	47.34	10,613	502,419	79,532	Dec 18 04:55 PM
Geary Richard S	EVP, Chief Development Officer	Dec 14 '23	Sale	49.58	10,613	526,236	72,961	Dec 18 04:55 PM
BENNETT C FRANK	EVP, Chief Scientific Officer	Dec 14 '23	Option Exercise	47.34	22,612	1,070,452	79,756	Dec 18 04:55 PM
BENNETT C FRANK	EVP, Chief Scientific Officer	Dec 14 '23	Sale	49.58	22,612	1,121,195	65,754	Dec 18 04:55 PM
KLEIN JOSEPH III	Director	Nov 15 '23	Sale	50.00	2,000	100,000	16,346	Nov 17 04:58 PM
Swayze Eric	EVP Research	Oct 16 '23	Option Exercise	0.00	125	0	125	Oct 18 06:40 PM
Swayze Eric	EVP Research	Oct 17 '23	Sale	47.95	52	2,493	73	Oct 18 06:40 PM
Monia Brett P	Chief Executive Officer	Oct 12 '23	Sale	46.00	3,770	173,420	118,111	Oct 16 04:35 PM
BENNETT C FRANK	EVP, Chief Scientific Officer	Sep 28 '23	Sale	46.50	4,460	207,390	65,754	Sep 29 05:20 PM
PARSHALL B LYNNE	Director	Sep 26 '23	Sale	45.13	10,000	451,268	82,588	Sep 28 06:03 PM
KLEIN JOSEPH III	Director	Sep 26 '23	Sale	45.13	2,000	90,254	18,346	Sep 28 06:03 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IONS

Ionis Pharmaceuticals Inc

Upgrade your FINVIZ experience